Cencora, Inc. $COR Shares Acquired by CenterBook Partners LP

Key Points

• CenterBook Partners increased its Cencora holdings by 152.4% in the third quarter, adding 8,306 shares to reach 13,757 shares valued at about $4.13 million.
• Cencora beat quarterly earnings and revenue estimates, reporting EPS of $4.66 and revenue of $88.35 billion, up 5.5% year over year.
• The company raised its quarterly dividend from $0.60 to $0.66 per share; analysts’ consensus rating is “Moderate Buy,” with an average price target of $368.73.

CenterBook Partners LP raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 152.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,757 shares of the company's stock after acquiring an additional 8,306 shares during the period. CenterBook Partners LP's holdings in Cencora were worth $4,131,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Cencora in the second quarter worth about $5,154,136,000. Bank of America Corp DE bought a new stake in shares of Cencora during the second quarter worth about $1,056,625,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Cencora during the 2nd quarter worth approximately $483,772,000. Legal & General Group Plc acquired a new position in Cencora in the 2nd quarter valued at approximately $339,556,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Cencora in the 2nd quarter valued at approximately $313,668,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Trending Headlines about Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat quarterly expectations, reporting EPS of $4.66 versus estimates of $4.58 and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year. The company also issued a stronger fiscal 2027 earnings outlook, reinforcing expectations for continued growth. Cencora stock enters fiscal 2027 with stronger earnings outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 from $388 and maintained an “outperform” rating, signaling confidence in potential upside.
• Positive Sentiment: Cencora raised its dividend, adding to its appeal for income-focused investors amid market uncertainty. Stocks that hiked dividends
• Neutral Sentiment: The company is realigning its corporate structure. The available report headline does not specify the changes or their expected financial impact. Cencora realigning corporate structure
• Negative Sentiment: Despite Cencora’s earnings beat, shares came under pressure after rival Cardinal Health reported results, prompting concern about relative performance and contributing to a short-term pullback. Cencora drops while rival Cardinal Health posts a beat

Analysts Set New Price Targets

COR has been the subject of several analyst reports. Bank of America raised their target price on Cencora from $285.00 to $310.00 in a research report on Tuesday, July 21st. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $330.00 price target on shares of Cencora in a research report on Tuesday, September 8th. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Wells Fargo & Company lifted their price objective on shares of Cencora from $331.00 to $395.00 and gave the company an "overweight" rating in a research note on Tuesday, August 11th. Finally, Citigroup reaffirmed a "buy" rating on shares of Cencora in a research note on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus target price of $368.73.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the business's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president owned 19,455 shares of the company's stock, valued at $6,305,754.60. The trade was a 36.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.38% of the company's stock.

Cencora Stock Down 1.9%

COR opened at $333.38 on Friday. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.01, a current ratio of 0.94 and a quick ratio of 0.58. The company's 50-day moving average is $325.07 and its 200 day moving average is $317.28. The firm has a market capitalization of $63.62 billion, a P/E ratio of 18.60, a PEG ratio of 1.73 and a beta of 0.58.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping the consensus estimate of $4.58 by $0.08. The firm had revenue of $88.35 billion for the quarter, compared to analysts' expectations of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The company's quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm earned $3.84 EPS. Research analysts expect that Cencora, Inc. will post 19.58 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be given a dividend of $0.66 per share. This is a boost from Cencora's previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, November 13th. Cencora's dividend payout ratio (DPR) is 13.39%.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.